open access

Vol 4, Supp. B (2013)
Case report
Published online: 2013-10-25
Get Citation

Complete molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase intolerant to imatinib and dasatinib

Tomasz Sacha

open access

Vol 4, Supp. B (2013)
CASE REPORTS
Published online: 2013-10-25

Abstract

Non-hematological toxicity of imatinib (IM) and dasatinib could result from more potent inhibition of other than bcr/abl1 tyrosine kinases and inhibition of additional pathways related to SRC kinase family. The case of a patient with chronic myelogenous leukemia in chronic phase who permanently discontinued IM due to extensive skin leasions, and dasatinib administered as a second-line treatment due to recurrent pericardiac effusions is described. Under IM as well as under dasatinib therapy an optimal response according to European LeukemiaNet criteria was achieved. After introduction of nilotinib neither signs of IM cross-intolerance nor reoccurrence of pericardiac effusion were noted. After 9 months of therapy with nilotinib the number of bcr/abl1 transcripts was reduced by 1 logarithm and reached the level recognized previously as a complete molecular response which is durable (follow-up 21 months).

Abstract

Non-hematological toxicity of imatinib (IM) and dasatinib could result from more potent inhibition of other than bcr/abl1 tyrosine kinases and inhibition of additional pathways related to SRC kinase family. The case of a patient with chronic myelogenous leukemia in chronic phase who permanently discontinued IM due to extensive skin leasions, and dasatinib administered as a second-line treatment due to recurrent pericardiac effusions is described. Under IM as well as under dasatinib therapy an optimal response according to European LeukemiaNet criteria was achieved. After introduction of nilotinib neither signs of IM cross-intolerance nor reoccurrence of pericardiac effusion were noted. After 9 months of therapy with nilotinib the number of bcr/abl1 transcripts was reduced by 1 logarithm and reached the level recognized previously as a complete molecular response which is durable (follow-up 21 months).
Get Citation

Keywords

chronic myelogenous leukemia, tyrosine kinase inhibitors, non-hematological toxicity, pericardiac effusions, imatinib, dasatinib, nilotinib in third-line treatment

About this article
Title

Complete molecular response achieved on the third-line nilotinib therapy in a patient with chronic myelogenous leukemia in chronic phase intolerant to imatinib and dasatinib

Journal

Hematology in Clinical Practice

Issue

Vol 4, Supp. B (2013)

Article type

Case report

Pages

4-6

Published online

2013-10-25

Keywords

chronic myelogenous leukemia
tyrosine kinase inhibitors
non-hematological toxicity
pericardiac effusions
imatinib
dasatinib
nilotinib in third-line treatment

Authors

Tomasz Sacha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.